21 industry stories, filterable by segment, category and keyword.
H1 revenue RMB 3.607B (+13.13% YoY); net profit attributable to shareholders RMB 520M (-15.71%); deduct-non-recurring net profit RMB 525M (-7.30%); operating cash flow RMB 822M (+17.18%); total assets RMB 20.83B, net assets RMB 17.74B; no dividend. Full-year 2026 revenue guided to grow 19%–22%.
H1 revenue RMB 3,701.4M (+37.0% AER / +41.5% CER), gross profit RMB 1,371.3M (+40.6%), adjusted net profit attributable to owners RMB 1,027.3M (+37.4%) at a 27.8% margin; 814 global clients, 328 iCMC programs, backlog ~US$2.0B (+50.4%); Singapore XmAb/XBCM3 achieved GMP release in August and BioDlink integration completed.
Excluding a RMB 330M impairment from terminating the Slovenia project, continuing-operations net profit reached RMB 92.3M, up ~329% YoY. Gross margin improved by nearly 5 ppts; CGT and New Molecules order intake grew 75% and 84% respectively.
WuXi AppTec's Research Chemistry Services (RCS) shortened a client's steroid synthesis from 7 steps to 3 while doubling yield; two years later, when kg-scale failed, RCS validated across four scales and introduced continuous precipitation, cutting 100g production from two weeks to four days — winning deep collaboration.
H1 2026 CDMO revenue reached RMB 199M (+157.0% YoY); cumulative customers totaled 116 (16 overseas); 134 CMC projects with 14 added in H1; first commercial-CDMO order secured for Lepu Biopharma's ADC Meiyouheng®; backlog RMB 391M (+95.5% YoY). WuXi XDC completed its tender on 2026-03-31 and held ~60.67% as of end-June.
CDMO services new orders jumped over 50% with segment revenue of RMB 1.88B (+32.78%); the company guides 15–20% full-year revenue growth. Revenue from the global top-20 pharma clients surged 31.95%.
Small-molecule players extend into linker-payloads, biologics players extend from mAbs into conjugation, and large CDMOs fill gaps in drug product and fill-finish — different starting points, the same destination: integrated XDC. China's H1 2026 license-out value neared USD 100B.
A Phase 2 triple stapled peptide project that stalled at another CDMO was transferred to WuXi AppTec. Through integrated WuXi TIDES execution — in-house UAA supply in 6 weeks, re-engineered RCM lifting crude purity 33%, and a metal-scavenging step cutting residual ruthenium ~75-fold — kilogram-scale GMP API was delivered in 8 months and Phase 2 CTM released in 11.
BCM3 offers 200–2,000 L antibody-intermediate batches and up to 2,000 L conjugated drug substance batches. From announcement to GMP release took only two and a half years, marking a new stage in the company's "China + Singapore" dual-site global capacity layout.
H1 gross profit rose 26% to RMB 1.38B and net profit grew 23.7% to RMB 617M, completing a Q2 inflection after a weak Q1. Chemical macromolecule CDMO backlog keeps doubling; 52 clinical peptide programs include 19 obesity-related projects.
In 2026, with domestic biotech funding cold and legacy Western CDMOs retreating, top players are moving in opposite directions — WuXi turning "M&A + guaranteed orders" into a capacity harvester, while Lonza and Catalent use "divestment + refocusing" as a margin-repair playbook.
The 10,000+ sqm site offers process development, drug substance and drug product capabilities, with the deal expected to close in Q3 2026 — the latest move in WuXi's counter-cyclical capacity buying at domestic asset-price lows.
Suzhou Porton Bio received the license from the Jiangsu MPDA, qualifying it for commercial CGT contract manufacturing. H1 CGT new orders grew ~75% YoY; lentiviral platform material localization exceeds 96%.
Adjusted non-IFRS net profit of RMB 11.57B, up 83.2% YoY; backlog of RMB 66.4B, up 25.2%; full-year revenue guidance raised to RMB 58.5–60.5B. Attributable net profit topped RMB 10B in H1 for the first time.
Plants 1–4 ran at full utilization with operating profit of KRW 586.4B and an operating margin of 44.4%; Plant 5 PPQ batches are ramping, and the company expects to hit the upper end of its 15–20% full-year revenue growth guidance.
H1 sales of CHF 3.4B with a CORE EBITDA margin of 34.8%; Advanced Synthesis posted CER sales growth of +27.7% with a 48.1% margin. The Visp large-scale mammalian facility began commercial operations, and a new ADC fill-finish line is being added in Stein.
From 982 integrated projects at end-April 2026 to 1,000 by July, the project pool keeps expanding — complex molecules now exceed 50% of the portfolio, with bispecific/multispecific antibodies as a key growth engine.
The all-cash public tender offer for the Swiss peptide CDMO is expected to close by end-2026, adding six cGMP plants across Belgium, France, India, Sweden and the US — a major step in Samsung's multi-modality strategy.
The new capacity, inside an existing GMP facility, is expected to be operational in 2028 and will support both clinical and commercial programs, complementing Lonza's antibody, conjugation and fill-finish ecosystem in Visp and Stein.
The deal adds 60,000 L of drug substance capacity (2×20,000 L + 2×10,000 L bioreactors) and establishes the company's first US manufacturing presence. Once Songdo Bio Campus II is complete, total capacity will reach 1.385M L.
643 cumulative clients, 252 integrated CMC programs (226 integrated ADC projects), 18+ PPQ projects; the planned Jiangyin payload-linker facility will have capacity equal to five times the current Wuxi base.
No matching stories.